Document:

EX-10.19(b)

 Exhibit 10.19(b) 

AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT 

THIS Amendment No.1 to Exclusive License Agreement (“Amendment”) is made and entered into this 10th day of September 2014 (“Effective Date”), by and between the Mayo Foundation for Medical Education and Research (“Mayo”) having its principal place of business at 200 First
Street SW, Rochester, MN 55905, and Cenexys, Inc., a Delaware corporation, having a place of business at 1700 Owen Street, Suite 535 San Francisco, CA 94158 (“Company”), for purposes of confirming the parties’ intent and agreement as
set forth herein. 
 BACKGROUND 

May and Company are parties to an Exclusive License Agreement, with an effective date of the
28th day of June, 2013 (“Agreement”), which confirms the parties’ intent and agreement to grant an exclusive license to Mayo’s certain patent rights and a nonexclusive license
to certain know-how. Mayo and Company wish to amend the Agreement as set forth in this Amendment No. 1, and, accordingly, Mayo and Company agree as follows: 

AMENDED TERMS 
 Exhibit A in its entirety will be
deleted and replaced with the exhibit attached to this Amendment No. 1. 
 All other terms of the Agreement shall remain in full force
and effect for the term of the Agreement and as set forth in the Agreement. 
 IN WITNESS WHEREOF, Mayo and Company hereby enter into this Amendment
No. 1, effective as of the date first set forth above. 
  

											
	Cenexys, Inc.	 		 		 	Mayo Foundation for Medical Education and Research
						
	By:	 	 /s/ Nathaniel E. David
	 		 	        	 	By:	 	 James A. Rogers, III

		 	Nathaniel E. David, Ph.D.	 		 		 		 	James A. Rogers, III
		 	CEO	 		 		 		 	Assistant Secretary

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

PATENT RIGH 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.19(c)

 Exhibit 10.19(c) 

AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT 

THIS Amendment No.2 to Exclusive License Agreement (“Amendment 2”) is made and entered into this 17th day of November 2014
(“Effective Date of Amendment 2”), by and between the Mayo Foundation for Medical Education and Research (“Mayo”) having its principal place of business at 200 First Street SW, Rochester, MN 55905, and Cenexys, Inc., a Delaware
corporation, having a place of business at 1700 Owen Street, Suite 535 San Francisco, CA 94158 (“Company”), for purposes of confirming the parties’ intent and agreement as set forth herein. 

BACKGROUND 
 Mayo and Company are
parties to an Exclusive License Agreement, with an effective date of the 28th day of June, 2013 (“Agreement”), which confirms the parties’ intent and agreement to grant an exclusive
license to Mayo’s certain patent rights and a nonexclusive license to certain know-how along with the first Amendment to the Agreement. Mayo and Company wish to amend the Agreement as set forth in this
Amendment No. 2, and, accordingly, Mayo and Company agree as follows: 
 AMENDED TERMS 

The first clause of Section 3.1 which reads: 

“In consideration for the rights and licenses granted by Mayo to Company herein and the research development support agreed to by Mayo
under Section 3.11,” 
 is hereby amended to read as follows: 

“As partial consideration for the rights and licenses granted by Mayo to Company herein as of the end of the IP Capture Period,”

 All other terms of the Agreement and the first Amendment shall remain in full force and effect for the term of the Agreement and as set
forth in the Agreement. 
 IN WITNESS WHEREOF, Mayo and Company hereby enter into this Amendment No. 2, effective as of the date first set forth above.

  

													
	Cenexys, Inc.	 		 	 Mayo Foundation for Medical Education and Research

						
	 By:
	 	 /s/ Nathaniel E. David
	 		 		 	 By:
	 	 /s/ James A. Rogers, III

		 	Nathaniel E. David, Ph.D.	 		 		 		 	 James A. Rogers, III

		 	CEO	 		 		 		 	Assistant SecretaryEX-10.19(d)

 Exhibit 10.19(d) 

AMENDMENT NO. 3 TO EXCLUSIVE LICENSE AGREEMENT 

THIS Amendment No. 3 to Exclusive License Agreement (“Amendment 3”) is made and entered into this 5th day of May, 2015
(“Effective Date of Amendment 3”), by and between the Mayo Foundation for Medical Education and Research (“Mayo”) having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905, and Unity Biotechnology,
Inc. (formerly known as Cenexys, Inc.), a Delaware corporation, having a place of business at 1700 Owen Street, Suite 535 San Francisco, California 94158 (“Company”), for purposes of confirming the parties’ intent and agreement as set
forth herein. 
 BACKGROUND 

Mayo and Company are parties to an Exclusive License Agreement, with an effective date of the 28th day of June, 2013 (“Agreement”),
which confirms the parties’ intent and agreement to grant an exclusive license to Mayo’s certain patent rights and a nonexclusive license to certain know-how along with Amendment No. I and Amendment
No. 2 to the Agreement. Mayo and Company wish to amend the Agreement as set forth in this Amendment No. 3, and, accordingly, Mayo and Company agree as follows: 

AMENDED TERMS 
 Exhibit A in its entirety will be
deleted and replaced with the exhibit attached to this Amendment No. 3. 
 All other terms of the Agreement and Amendment No. 2
shall remain in full force and effect for the term of the Agreement and as set forth in the Agreement. 
 IN WITNESS WHEREOF, Mayo and Company hereby enter
into this Amendment No. 3, effective as of the date first set forth above. 
  

									
	Unity Biotechnology, Inc.	 		 	Mayo Foundation for Medical Education and Research
					
	By:	 	 /s/ Nathaniel E. David
	 		 	By:	 	 /s/ Daniel D. Estes

	Name:	 	Nathaniel E. David, PhD	 		 	Name:	 	Daniel D. Estes
	Title:	 	President	 	        	 	Title:	 	Assistant Treasurer

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

PATENT RIGHTS 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.19(e)

 Exhibit 10.19(e) 

AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT 

THIS Amendment No. 4 to Exclusive License Agreement (“Amendment No. 4”) is made and entered into this 15th day of
September 2016 (“Effective Date of Amendment No. 4”), by and between the Mayo Foundation for Medical Education and Research (“Mayo”) having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905,
and Unity Biotechnology, Inc. (formerly known as Cenexys, Inc.), a Delaware corporation, having a place of business at 3280 Bayshore Blvd, Brisbane (“Company”), for purposes of confirming the parties’ intent and agreement as set forth
herein. 
 BACKGROUND 
 Mayo and Company are
parties to an Exclusive License Agreement, with an effective date of the 28th day of June, 2013 (“Agreement”), which confirms the parties’ intent and agreement to grant an exclusive
license to Mayo’s certain patent rights and a nonexclusive license to certain know-how along with Amendment No. 1, Amendment No. 2, and Amendment No. 3 to the Agreement. Mayo and Company
agree that there is no need to amend Exhibit C listing the proprietary research tools. Mayo and Company wish to amend the Agreement as set forth in this Amendment No. 4, and, accordingly, Mayo and Company agree as follows: 

AMENDED TERMS 
 1.
    Exhibit A in its entirety will be deleted and replaced with the exhibit attached to this Amendment No. 4. 
 All
other terms of the Agreement and Amendment No. 3 shall remain in full force and effect for the term of the Agreement and as set forth in the Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, Mayo and Company hereby enter into this Amendment No. 4, effective as of the date first
set forth above. 
  

									
	Unity Biotechnology, Inc.	 		 	Mayo Foundation for Medical Education and Research
					
	By:	 	 /s/ Nathaniel E. David
	 	        	 	By:	 	 /s/ Daniel D. Estes

		 		 		 	Name:	 	Daniel D. Estes
		 		 		 	Title:	 	Assistant Treasurer

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 

PATENT RIGHTS 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.19(f)

 Exhibit 10.19(f) 

Unity Biotechnology 
 3280 Bayshore Blvd., Suite 100 

Brisbane, CA 94005 
 September 15, 2016

 Mayo Foundation for Medical Education and Research 

200 First Street SW 
 Rochester,
MN 55905 
 Attn: Daniel D. Estes 

re:    Addendum to Amendment 4 to Exclusive License Agreement 

Dear Daniel: 
 As you know, Mayo
Foundation for Medical Education and Research (“Mayo”) and Unity Biotechnology, Inc. (“Unity”) are parties to an Exclusive License Agreement (“Agreement”), effective as of June 28, 2013. Pursuant to
Section 2.2 of the Agreement, Mayo granted to Unity an option to include within the licenses granted under the Agreement any “Additional Developments” (as defined in the Agreement) developed during the IP Capture Period (as defined in
the Agreement). In connection with the grant of such option, Mayo further agreed to promptly notify Unity in writing of all Additional Inventions developed by Mayo personnel during the IP Capture Period and to provide Unity with a suitable
description of such Additional Invention together with such other information as Unity may reasonably request for purposes of enabling Unity to assess its interest in such Additional Developments. 

As requested by Mayo, Unity is providing this letter to confirm that it has received timely notice of the Additional Inventions listed in
Appendix A hereto (each such additional Invention identified by Mayo’s designated case number) and to provide a summary of which Additional Inventions it has elected to license, which it has declined to license and which Additional Inventions
are still under consideration. Appendix A indicates with respect to each Additional Invention whether 1) Unity will be declining a license 2) Unity is exercising its option to a license, or 3) Unity would like to learn more about the Additional
Invention from the Mayo innovators before deciding whether to exercise its option. Additionally, as requested by Mayo, Appendix A, also lists those patent applications that have been filed as of the current date for those Additional Inventions
exercised under the option. 
 If Mayo is in agreement with the summary provided in Appendix A, we ask that you please so indicate by
signing below and kindly returning a copy of this letter to me. A duplicate original is enclosed for your records. If you have any questions or comments, please do not hesitate to contact me at [***] or by
e-mail at [***]. Thank you. 
 Sincerely, 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	
	 /s/ Nathaniel E. David

	Nathaniel E. David, Ph.D.
	CEO
	Unity Biotechnology, Inc.

 Agreed and accepted: 
 Mayo
Foundation for Medical Education and Research 
  

			
	 /s/ Daniel D. Estes

	Name:	 	Daniel D. Estes
	Title:	 	Assistant Treasurer
	Date:	 	9-23-2016

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 APPENDIX A 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]